news

The organisation team of the international Drug-Drug Interaction (DDI) Workshop in Marbach Castle on Lake Constance is happy to report the great acceptance and success of the events series in its fourth year. More than 70 drug development experts and representatives of health authorities participated in the scientific event “DDI 2013 – 4th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions”. Feedback from participants has been overwhelmingly positive and has motivated the organisation team to start making preparations for next year’s anniversary event immediately. The date for the fifth international DDI Workshop has been set for 25th – 27th May 2014.

The organization team of the 4th DDI workshop reports that more than 70 international drug development experts and representatives from health authorities take part at the scientific meeting ”DDI 2013 – 4th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions” at Marbach Castle, Lake Constance.

Radolfzell, Germany, April 22nd 2013: The organization team of the International DDI Workshop announces the final programme of the DDI 2013 – 4th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions, which will take place from May 26th to 28th 2013 at Marbach Castle, Germany.

Radolfzell, Germany, December 5th 2012: Since 5 years the cr.appliance team with its current staff and portfolio counsels pharmaceutical companies in drug development, especially in the early stages (preclinical / clinical interface). Big international as well as mid-sized companies and biotec enterprises particularly benefit from cr.appliance’s specific expertise.

The organisation team of the Third International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. The participants of the DDI Workshop commended the very high scientific level of the presentations and valuable and inspiring discussions of the different topics. Without a doubt, the DDI Workshop at Marbach Castle is a well established platform for the annual exchange between experts, scientists, members of the industry and regulatory bodies regarding DDI affairs. This year more than 80 experts from 14 countries attended the DDI Workshop. The speakers came from 6 different countries (USA, Germany, Great Britain, Finland, Sweden, and New Zealand), thereof 5 from the US. They presented scientific news, the content of the draft guidelines and state of the art lectures. The scientific sessions covered different aspects to current regulatory issues, UGTbased DDIs, transporter-based DDIs and pharmacodynamic DDIs.

The organisation team reports the final programme of the DDI 2012 – 3rd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions. The topics of the 3rd Marbach Castle meeting, which will take place from May 6 th to 8 th 2012, will be covered by international scientists and distinguished experts from academia, pharmaceutical companies, contract research organizations, consultancies and regulatory bodies. The programme will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs.

The organisation team of the Second International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. This was also confirmed by the outcome of a feedback survey given to the participants. Both the scientific level of the presentations and discussions as well as the breadth of the topics covered were judged positively. Many already expressed interest in the third DDI Workshop in 2012. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts, scientists, members of the industry and regulatory bodies regarding DDI affairs.

The organisation team of the 2nd DDI workshop reports that more than 60 drug development and interaction experts from different countries take part at the scientific meeting ”DDI 2011 – 2nd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions” at Marbach Castle, Lake Constance.

The organisation team reports the final program of the DDI 2011 – 2nd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions. The topics of the 2nd Marbach Castle meeting on regulatory and scientific aspects of drugdrug interactions (DDI), which will take place from May 1st to 3rd 2011, will be covered by renowned international scientists and experts from academia, pharmaceutical companies, contract research organizations, and consultancies. The program will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs. The organizers are pleased to announce additional distinguished speakers from the USA (Michael Bolger, Uwe Christians, Andrew Parkinson, Alex Sparreboom, Karthik Venkatakrishnan) and Germany (Thomas Gramatte´, Wilhelm Haverkamp, Bernd Liedert, Christian de Mey).

The organisation team reports a big success regarding the drug-drug-interaction (DDI) workshop, which was held from May 30th to June 01st at Marbach Castle, Lake Constance in Germany. More than 60 experts from 11 countries and 5 participants at the industry exhibition joined the meeting on DDIs. New methods and approaches for the investigation of drug candidates have become necessary due to the increasing complexity of this scientific area. Changes in the existing guideline on drug interactions must follow. Recently the European Medicines Agency (EMA) published a draft of the revised guideline, which was discussed in several talks at the DDI Workshop. In the US a new version of the existing FDA drug interaction guideline is under discussion but not published yet. Discussion of the current scientific status between representatives of the industry, regulatory bodies, and academia are of great importance and were successfully realized at the DDI Workshop.